All News
Bayer joined in the $50 million Series A for San Francisco’s Indapta Therapeutics.
As AstraZeneca released its 2021 annual financial report, a BBC documentary suggested that the way scientists and politicians politicized its COVID-19 vaccine may have cost lives.
Recent research supports a link between vitamin D deficiency and severe COVID-19. Here’s a look.
It’s uncertain if the origins of COVID-19 will ever be determined, but the current top theories split about evenly between a lab leak from the Wuhan Institute of Virology and a natural evolution from bats to animals to humans at a Wuhan “wet market.”
The EUA request is based on the Phase II study that showed treatment with ensovibep reduced the viral load from the SARS-CoV-2 virus within eight days of use compared to placebo.
Teva Pharmaceuticals reported solid earnings for the full year of 2021, posting $15.9 billion in revenues alongside gains of $4.1 billion from the fourth quarter alone.
Merck has announced positive results from its Phase III KEYNOTE-522 study on the use of KEYTRUDA alongside chemotherapy in high-risk early-stage triple-negative breast cancer.
REGENXBIO presented results from its ongoing Phase I/II trial of RGX-111, an investigational one-time gene therapy for people with Mucopolysaccharidosis Type I (MPS I).
Deepcell, a biotechnology company spun out of Stanford University in 2017, focuses on quantifying and understanding morphology – part of the cell’s phenotype.
Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.
As GSK moves into the new year, Chief Executive Officer Emma Walmsley predicted 2022 will be a “landmark year” for the company.
72% of employers are currently experiencing a decrease in the volume of candidates applying to their jobs.
Seismic Therapeutic, Inc. announced its launch and financing of $101 million to fund two new programs and further develop its existing IMPACT™ platform.
Johnson & Johnson has temporarily paused production of its COVID-19 vaccine at its manufacturing site in The Netherlands.
Ventus Therapeutics has raised $140 million in a Series C financing round less than two years after launching to develop therapies aimed at diseases of the innate immune system.
The FDA is slowing down the process of potentially approving dozens of new medications initially developed for the Chinese market.
A week after Novavax submitted its Emergency Use Authorization materials to the FDA for its COVID-19 vaccine candidate. reports are coming out about the company’s problems with the production and delivery.
An entire lot of the male erectile dysfunction drug The Red Pill is being pulled out of the market following the discovery that it contains some traces of tadalafil.
The COVID-19 pandemic has seen a full-blown effort from biopharma and researchers to develop new drugs and test old ones against the disease, with highly mixed results.
enGene announced positive results from its LEGEND Phase I/II clinical trial for treating high-grade NMIBC in patients with carcinoma in situ that are unresponsive to BCG treatment.